Clinical trials data
Continuous Performance Test in schizophrenia and psychosis trials: 78 registered studies
Every registered schizophrenia and psychosis study on ClinicalTrials.gov that names the Continuous Performance Test in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered schizophrenia and psychosis studies name it in an outcome measure
- 78
- Name it in a primary outcome, 36%
- 28 of 78
Tests named in the same studies
- 1
Verbal Learning28 studies, 14 as a primary outcome
- 2
Category Fluency27 studies, 9 as a primary outcome
- 3
AX Continuous Performance Test24 studies, 12 as a primary outcome
- 4
Trail Making Test21 studies, 8 as a primary outcome
- 5
Symbol Coding15 studies, 5 as a primary outcome
- 6
Digit Span Test15 studies, 4 as a primary outcome
- 7
N-Back Task13 studies, 5 as a primary outcome
- 8
Verbal Fluency11 studies, 4 as a primary outcome
- 9
Card Sorting Test (Berg)10 studies, 3 as a primary outcome
- 10
Letter-Number Sequencing Task9 studies, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 2 | 2 |
| 2005 | 2 | 1 |
| 2006 | 2 | 2 |
| 2007 | 5 | 2 |
| 2008 | 1 | 0 |
| 2009 | 1 | 0 |
| 2010 | 3 | 2 |
| 2011 | 4 | 1 |
| 2012 | 2 | 0 |
| 2013 | 4 | 1 |
| 2014 | 8 | 1 |
| 2015 | 3 | 1 |
| 2016 | 5 | 1 |
| 2017 | 3 | 2 |
| 2018 | 5 | 1 |
| 2019 | 4 | 2 |
| 2020 | 2 | 0 |
| 2021 | 5 | 2 |
| 2022 | 4 | 1 |
| 2023 | 2 | 2 |
| 2024 | 2 | 0 |
| 2025 | 3 | 0 |
| 2026 | 3 | 2 |
Phases and study sizes
By phase
- Phase 12 studies, 0 as a primary outcome
- Phase 1/21 studies, 0 as a primary outcome
- Phase 225 studies, 4 as a primary outcome
- Phase 2/32 studies, 0 as a primary outcome
- Phase 33 studies, 2 as a primary outcome
- Phase 410 studies, 5 as a primary outcome
- Not applicable34 studies, 17 as a primary outcome
- Observational1 studies, 0 as a primary outcome
Participants per study
- Phase 268 median, 45 to 90
- Phase 477 median, 59 to 102
- Not applicable65 median, 40 to 88
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 25 | 68 | 45 to 90 |
| Phase 4 | 10 | 77 | 59 to 102 |
| Not applicable | 34 | 65 | 40 to 88 |
When schizophrenia and psychosis trials measure it
Latest time point of each outcome
- Within a day9 outcomes, 4 as a primary outcome
- Up to 4 weeks13 outcomes, 7 as a primary outcome
- 1 to 3 months26 outcomes, 10 as a primary outcome
- 3 to 6 months16 outcomes, 7 as a primary outcome
- 6 to 12 months5 outcomes, 0 as a primary outcome
- 1 to 2 years2 outcomes, 0 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
71 of the 71 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting16 studies, 4 as a primary outcome
- Not yet recruiting1 studies, 1 as a primary outcome
- Completed43 studies, 18 as a primary outcome
- Stopped early5 studies, 0 as a primary outcome
- Status unknown13 studies, 5 as a primary outcome
What they test
- Behavioral17 studies, 7 as a primary outcome
- Drug44 studies, 13 as a primary outcome
- Device13 studies, 6 as a primary outcome
- Dietary supplement3 studies, 1 as a primary outcome
- Biological1 studies, 0 as a primary outcome
- Other12 studies, 6 as a primary outcome
- None given1 studies, 0 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States37 studies, 14 as a primary outcome
- Taiwan15 studies, 4 as a primary outcome
- China5 studies, 2 as a primary outcome
- Canada4 studies, 2 as a primary outcome
- Spain4 studies, 1 as a primary outcome
- France2 studies, 1 as a primary outcome
- Norway2 studies, 1 as a primary outcome
- Germany1 studies, 0 as a primary outcome
- Holy See1 studies, 0 as a primary outcome
- Ireland1 studies, 1 as a primary outcome
- Italy1 studies, 1 as a primary outcome
- Poland1 studies, 1 as a primary outcome
14 countries in all. A study with sites in several counts in each; 3 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed schizophrenia and psychosis studies that name the Continuous Performance Test: 32 of 43, 74%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed schizophrenia and psychosis studies that name the Continuous Performance Test | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 13, 30% | 776, 10% |
| Results on ClinicalTrials.gov only | 12, 28% | 1,139, 14% |
| A results paper only | 7, 16% | 1,711, 22% |
| Neither | 11, 26% | 4,327, 54% |
The 78 studies
78 studies match. 28 name the Continuous Performance Test in a primary outcome. Median size 71 participants. Median time to the primary outcome: 10 weeks.
Loading 78 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 2 | 2 |
| 2005 | 2 | 1 |
| 2006 | 2 | 2 |
| 2007 | 5 | 2 |
| 2008 | 1 | 0 |
| 2009 | 1 | 0 |
| 2010 | 3 | 2 |
| 2011 | 4 | 1 |
| 2012 | 2 | 0 |
| 2013 | 4 | 1 |
| 2014 | 8 | 1 |
| 2015 | 3 | 1 |
| 2016 | 5 | 1 |
| 2017 | 3 | 2 |
| 2018 | 5 | 1 |
| 2019 | 4 | 2 |
| 2020 | 2 | 0 |
| 2021 | 5 | 2 |
| 2022 | 4 | 1 |
| 2023 | 2 | 2 |
| 2024 | 2 | 0 |
| 2025 | 3 | 0 |
| 2026 | 3 | 2 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 9, other 69. Interventional 77, observational 1.
As a primary outcomeSecondary or other outcomeThe Continuous Performance Test
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07834203 | Start2025 | PhaseObservational | ConditionsSchizophrenia and psychosis, Depression and bipolar disorder | Participants500 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07702526 | Start2026 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants160 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07226895 | Start2026 | PhasePhase 1/2 | ConditionsSchizophrenia and psychosis | Participants150 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07122895 | Start2025 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07006935 | Start2026 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06574360 | Start2024 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06562608 | Start2025 | PhasePhase 4 | ConditionsSchizophrenia and psychosis | Participants105 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06542640 | Start2024 | PhaseNot applicable | ConditionsSchizophrenia and psychosis, Healthy volunteers | Participants300 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06423651 | Start2022 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants160 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06340789 | Start2021 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06021197 | Start2023 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06003036 | Start2023 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants30 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05405946 | Start2019 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants50 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05240976 | Start2022 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05167396 | Start2022 | PhaseNot applicable | ConditionsSchizophrenia and psychosis, Healthy volunteers | Participants34 | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT05130853 | Start2021 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants48 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05102929 | Start2021 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants75 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05052853 | Start2021 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants48 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT04959201 | Start2020 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT04917302 | Start2020 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT04745143 | Start2018 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT04321759 | Start2021 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants378 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT04226898 | Start2022 | PhasePhase 2 | ConditionsSchizophrenia and psychosis | Participants68 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT04143308 | Start2019 | PhaseNot applicable | ConditionsSchizophrenia and psychosis, Aging, frailty and exercise | Participants90 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT04012684 | Start2019 | PhaseNot applicable | ConditionsSchizophrenia and psychosis | Participants48 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
Questions, answered from the data
How many schizophrenia and psychosis trials use the Continuous Performance Test?
78 registered schizophrenia and psychosis studies on ClinicalTrials.gov name it in an outcome measure, 28 of them in a primary outcome: 12% of the condition's 640 studies with a cognitive outcome, against 4% of all of them. It is the 4th most named test in schizophrenia and psychosis trials.
Which tests do schizophrenia and psychosis trials use with the Continuous Performance Test?
Verbal Learning (28 studies), Category Fluency (27 studies) and the AX Continuous Performance Test (24 studies).
How many participants do phase 2 schizophrenia and psychosis trials that use the Continuous Performance Test enroll?
Half of the phase 2 studies that name it enroll 68 participants or fewer, and the middle half enroll 45 to 90. 25 of them give a size.
When do schizophrenia and psychosis trials measure the Continuous Performance Test?
Half of the primary outcomes that name the Continuous Performance Test are measured within 10 weeks of the start, and the middle half from 3 weeks to 14 weeks. 28 primary outcomes give a duration.
How many completed schizophrenia and psychosis trials that use the Continuous Performance Test have reported results?
32 of the 43 completed studies that name it, 74%, have reported results: 25 posted them on ClinicalTrials.gov, 20 have a results paper linked to the registry record, and 13 did both. The other 11 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run the Continuous Performance Test in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.